Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

Friday, April 28, 2023
Registration & Breakfast: 7:30 AM – 8:00 AM CT
Scientific Session: 8:00 AM- 10:00 AM CT
McCormick Place - South Building
In-Person + Live Streaming Satellite Symposium

Treatment of prostate cancer is challenging because of the heterogeneity of tumors and lack of clear recommendations about which therapeutic strategies should be used at various time points during disease progression. Clinicians face the difficult task of selecting and sequencing therapies for management castrate-resistant prostate cancer (CRPC) that require careful consideration of the patient’s clinical profile.

This Medical Crossfire®, one of PER’s signature educational formats, will be a live, hybrid satellite symposium held on Friday, April 28, 2023. In this educational program, renowned experts will engage in spirted discussions and debates on the practical implications of sequencing therapeutic agents for mCRPC treatment as well as on the application of new data in clinical situations urologists are likely to encounter in real-world scenarios. The lively discussion will place new developments into clinical context to help you optimize care for your patients with mCRPC.

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Lantheus, and Sanofi.

Register here: https://bit.ly/3musxSv

This educational program is directed toward urologists, medical oncologists, radiation oncologists and other physicians interested in the treatment of prostate cancer.